Regenxbio Reports 97% Reduction in Injection Need for Wet AMD; Shares Rise Pre-Bell
MT Newswires Live
Oct 21, 2024
Regenxbio (RGNX) reported Monday a 97% reduction in anti-VEGF injections at nine months in a Phase II study of ABBV-RGX-314 for wet age-related macular degeneration, or AMD.
In the subretinal treatment of the second eye, 78% of patients remained injection-free, the company said. Visual acuity and retinal thickness were maintained, with no serious drug-related adverse events observed, it added.
The study is evaluating ABBV-RGX-314 as a potential one-time gene therapy to address the burden of lifelong injections in wet AMD, according to the company statement.
Shares of Regenxbio were up more than 4% in recent pre-market trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.